PMID- 37843639
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231214
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Print)
IS  - 0941-4355 (Linking)
VI  - 31
IP  - 12
DP  - 2023 Oct 16
TI  - Prevalence of opioid-induced adverse events across opioids commonly used for 
      analgesic treatment in Japan: a multicenter prospective longitudinal study.
PG  - 632
LID - 10.1007/s00520-023-08099-2 [doi]
LID - 632
AB  - PURPOSE: Although opioids have been shown to be effective for cancer pain, 
      opioid-induced adverse events (AEs) are common. To date, little is known about 
      the differences in risks of AEs by opioid type. This study was performed to 
      compare the prevalence of AEs across opioids commonly used for analgesic 
      treatment in Japan. METHODS: This study was conducted as a preplanned secondary 
      analysis of a multicenter prospective longitudinal study of inpatients with 
      cancer pain who received specialized palliative care for cancer pain relief. We 
      assessed daily AEs until termination of follow-up. We rated the severity of AEs 
      based on the Common Terminology Criteria for Adverse Events version 5.0. We 
      computed adjusted odds ratios for each AE (constipation, nausea and vomiting, 
      delirium, and drowsiness) with the following variables: opioid, age, sex, renal 
      dysfunction, and primary cancer site. RESULTS: In total, 465 patients were 
      analyzed. Based on the descriptive analysis, the top four most commonly used 
      opioids were included in the analysis: oxycodone, hydromorphone, fentanyl, and 
      tramadol. With respect to the prevalence of AEs among all analyzed patients, 
      delirium (n = 25, 6.3%) was the most frequent, followed by drowsiness (n = 21, 
      5.3%), nausea and vomiting (n = 19, 4.8%), and constipation (n = 28, 4.6%). The 
      multivariate logistic analysis showed that no single opioid was identified as a 
      statistically significant independent predictor of any AE. CONCLUSION: There was 
      no significant difference in the prevalence of AEs among oxycodone, fentanyl, 
      hydromorphone, and tramadol, which are commonly used for analgesic treatment in 
      Japan.
CI  - (c) 2023. The Author(s).
FAU - Hiratsuka, Yusuke
AU  - Hiratsuka Y
AD  - Department of Palliative Medicine, Takeda General Hospital, Aizu Wakamatsu, 
      Japan. hiratsuka.med.t@gmail.com.
AD  - Department of Palliative Medicine, Tohoku University Graduate School of Medicine, 
      Sendai, Japan. hiratsuka.med.t@gmail.com.
FAU - Tagami, Keita
AU  - Tagami K
AD  - Department of Palliative Medicine, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Inoue, Akira
AU  - Inoue A
AD  - Department of Palliative Medicine, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Sato, Mamiko
AU  - Sato M
AD  - Department of Palliative Medicine, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Matsuda, Yasufumi
AU  - Matsuda Y
AD  - Department of Palliative Medicine, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Kosugi, Kazuhiro
AU  - Kosugi K
AD  - Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, 
      Japan.
FAU - Kubo, Emi
AU  - Kubo E
AD  - Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, 
      Japan.
FAU - Natsume, Maika
AU  - Natsume M
AD  - Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, 
      Japan.
FAU - Ishiki, Hiroto
AU  - Ishiki H
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
FAU - Arakawa, Sayaka
AU  - Arakawa S
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
FAU - Shimizu, Masaki
AU  - Shimizu M
AD  - Department of Palliative Care, Kyoto-Katsura Hospital, Kyoto, Japan.
FAU - Yokomichi, Naosuke
AU  - Yokomichi N
AD  - Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital, 
      Hamamatsu, Japan.
FAU - Chiu, Shih-Wei
AU  - Chiu SW
AD  - Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Shimoda, Mayu
AU  - Shimoda M
AD  - Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Hirayama, Hideyuki
AU  - Hirayama H
AD  - Department of Palliative Nursing, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Nishijima, Kaoru
AU  - Nishijima K
AD  - Department of Palliative Care, Kyowakai Medical Corporation, Daini Kyoritsu 
      Hospital, Kawanishi, Japan.
FAU - Ouchi, Kota
AU  - Ouchi K
AD  - Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
FAU - Shimoi, Tatsunori
AU  - Shimoi T
AD  - Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
FAU - Shigeno, Tomoko
AU  - Shigeno T
AD  - Department of Palliative Nursing, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Yamaguchi, Takuhiro
AU  - Yamaguchi T
AD  - Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Miyashita, Mitsunori
AU  - Miyashita M
AD  - Department of Palliative Nursing, Tohoku University Graduate School of Medicine, 
      Sendai, Japan.
FAU - Morita, Tatsuya
AU  - Morita T
AD  - Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital, 
      Hamamatsu, Japan.
AD  - Research Association for Community Health, Hamamatsu, Japan.
FAU - Satomi, Eriko
AU  - Satomi E
AD  - Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan.
LA  - eng
GR  - 19EA1011/National Cancer Center Japan/
PT  - Journal Article
PT  - Multicenter Study
DEP - 20231016
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
RN  - 0 (Analgesics, Opioid)
RN  - CD35PMG570 (Oxycodone)
RN  - Q812464R06 (Hydromorphone)
RN  - 39J1LGJ30J (Tramadol)
RN  - UF599785JZ (Fentanyl)
SB  - IM
MH  - Humans
MH  - Analgesics, Opioid/adverse effects
MH  - Oxycodone
MH  - Hydromorphone/adverse effects
MH  - *Cancer Pain/drug therapy/epidemiology/chemically induced
MH  - *Tramadol
MH  - Prospective Studies
MH  - Japan/epidemiology
MH  - Prevalence
MH  - Longitudinal Studies
MH  - Fentanyl
MH  - Constipation/chemically induced
MH  - Nausea/chemically induced
MH  - Vomiting/chemically induced
MH  - *Delirium/drug therapy
PMC - PMC10579154
OTO - NOTNLM
OT  - Advanced cancer
OT  - Adverse event
OT  - Opioid
OT  - Specialized palliative care
COIS- The authors have reported the COI via ICMJE disclosure form. The corresponding 
      author has submitted the forms as supplementary files. The authors have no 
      conflicts of interest to declare that are relevant to the content of this 
      article.
EDAT- 2023/10/16 12:42
MHDA- 2023/10/23 01:18
PMCR- 2023/10/16
CRDT- 2023/10/16 11:07
PHST- 2023/07/09 00:00 [received]
PHST- 2023/10/02 00:00 [accepted]
PHST- 2023/10/23 01:18 [medline]
PHST- 2023/10/16 12:42 [pubmed]
PHST- 2023/10/16 11:07 [entrez]
PHST- 2023/10/16 00:00 [pmc-release]
AID - 10.1007/s00520-023-08099-2 [pii]
AID - 8099 [pii]
AID - 10.1007/s00520-023-08099-2 [doi]
PST - epublish
SO  - Support Care Cancer. 2023 Oct 16;31(12):632. doi: 10.1007/s00520-023-08099-2.